Article
Virology
Tiago Ferreira, Amit Kulkarni, Clemens Bretscher, Petr Nazarov, Jubayer A. Hossain, Lars A. R. Ystaas, Hrvoje Miletic, Ralph Roeth, Beate Niesler, Antonio Marchini
Summary: Studies have shown that galectin-1 plays a crucial role in the H-1PV life cycle and is overexpressed in various tumors including glioblastoma and pancreatic carcinoma.
Article
Oncology
Wenmo Liu, Xupu Wang, Xinyao Feng, Jiahao Yu, Xinyao Liu, Xinyuan Jia, Haihong Zhang, Hui Wu, Chu Wang, Jiaxin Wu, Bin Yu, Xianghui Yu
Summary: This study investigates the mechanism of using oncolytic adenoviruses for tumor immunotherapy and demonstrates that combination treatment with CD40 ligand can enhance the antitumor activity of oncolytic adenoviruses.
Review
Biochemistry & Molecular Biology
Guijin Tang, Dawei Wang, Xiangqian Zhao, Zhihua Feng, Qi Chen, Yangkun Shen
Summary: Oncolytic viruses (OVs) are effective gene therapy and immunotherapy drugs. The integration of exogenous genes into OVs, particularly the herpes simplex virus type 1 (HSV-1), has become a novel approach in OV therapy. The current mode of administration for HSV-1 oncolytic viruses is mainly through tumor in situ injection, which limits their application. Intravenous administration offers a solution, but is challenging due to the immune response against HSV-1, leading to clearance by the body's immune system and side effects. This review discusses different administration methods, with a focus on intravenous administration, and explores immune constraints and potential solutions to improve HSV-1 delivery for OV therapy.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
(2023)
Review
Oncology
Hayle Scanlan, Zachary Coffman, Jeffrey Bettencourt, Timothy Shipley, Debra E. Bramblett
Summary: This review provides an overview of HSV-1 as an oncolytic virus candidate and the genomic organization of T-VEC. The advantages and limitations of T-VEC compared to other HSV-1 oncolytic virus variants currently in clinical trials are discussed. Additionally, future directions for the use of HSV-1 oncolytic viruses as cancer therapy are explored.
FRONTIERS IN ONCOLOGY
(2022)
Review
Biochemistry & Molecular Biology
Shyambabu Chaurasiya, Yuman Fong, Susanne G. Warner
Summary: Oncolytic viruses are a new class of therapeutics that have shown promise in clinical trials, although their anti-tumor efficacy as monotherapy is modest. Most oncolytic viruses are well tolerated, even in immune-suppressed patients, at the currently defined highest feasible doses. Enhancing the potency of oncolytic viruses is necessary for more viruses to be used effectively in clinical settings, thus they are being studied in combination with other therapies for higher therapeutic benefits.
Article
Cell Biology
Junwen Zhang, Jialin Wang, Mingxin Li, Xiaodong Su, Yifu Tian, Peiwen Wang, Xianzhe Zhou, Guishan Jin, Fusheng Liu
Summary: Gliomas are aggressive intracranial tumors with high lethality and recurrence rates. The oncolytic virus HSV-1, specifically the strain oHSV-1 with gamma 34.5 and ICP47 gene deletions, has been shown to suppress glioma cell growth and invasion by downregulating the expression of invasion-related genes through the suppression of the transcription factor Sp1. These findings suggest that Sp1 may serve as a molecular marker for predicting the antitumor effects of oHSV-1 in glioma treatment.
CELLULAR SIGNALLING
(2023)
Article
Biotechnology & Applied Microbiology
Ryo Ishino, Yumi Kawase, Toshio Kitawaki, Naoshi Sugimoto, Maki Oku, Shumpei Uchida, Osamu Imataki, Akihito Matsuoka, Teruhisa Taoka, Kimihiro Kawakami, Toin H. van Kuppevelt, Tomoki Todo, Akifumi Takaori-Kondo, Norimitsu Kadowaki
Summary: Oncolytic herpes simplex virus type 1 (HSV-1) T-01 shows potential therapeutic effects on hematological malignancies, with its infection and oncolytic effects correlated to the expression of nectin-1. Further research is needed to explore the optimal efficacy of this treatment approach.
Article
Biochemistry & Molecular Biology
Wencai Qiu, Xiuyan Ding, Shitao Li, Yongming He, Liqian Zhu
Summary: The study demonstrates that BoHV-1 has oncolytic effects against human lung adenocarcinoma in vivo. BoHV-1 infection reduced HDAC protein levels in A549 cells and showed synergy with the HDAC inhibitor TSA. In the mouse xenograft model, BoHV-1 effectively infected tumors and suppressed tumor growth, potentially through interaction with HDACs.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
(2021)
Article
Biochemistry & Molecular Biology
Haiyan Zhou, Tangting Chen, Yongjie Li, Jingcan You, Xin Deng, Ni Chen, Tian Li, Youkun Zheng, Rong Li, Mao Luo, Jianbo Wu, Liqun Wang
Summary: This study found that Tie-2 is modified by AGEs in diabetes, leading to the inhibition of Ang-1 signaling activation and angiogenesis. This finding provides a novel mechanism for Ang-1/Tie-2 signal dysfunction and angiogenesis failure in diabetic ischemic diseases.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
(2022)
Article
Oncology
Chao Tian, Jiajia Liu, Hua Zhou, Jingfeng Li, Chunyang Sun, Wei Zhu, Yuxin Yin, Xiaopeng Li
Summary: HSV-aPD-1, a recombinant herpes simplex virus type 1 carrying anti-PD-1 monoclonal antibodies, demonstrates enhanced anti-tumor immune responses and T-cell infiltration, leading to effective tumor inhibition and potential clinical applications in tumors resistant to immune checkpoint inhibitors.
Article
Hematology
Maki Oku, Ryo Ishino, Shumpei Uchida, Osamu Imataki, Naoshi Sugimoto, Tomoki Todo, Norimitsu Kadowaki
Summary: This study demonstrates that the third-generation oncolytic HSV-1 virus, T-01, has a direct oncolytic effect on human myeloma cells. The presence of peripheral blood mononuclear cells can enhance the anti-tumor effect, with pDCs and NK cells dominating the immune activation. Lenalidomide is likely to augment the anti-myeloma effect of HSV-1.
BRITISH JOURNAL OF HAEMATOLOGY
(2021)
Review
Pharmacology & Pharmacy
Alberto Reale, Arianna Calistri, Jennifer Altomonte
Summary: Oncolytic viruses are a new class of therapeutic agents with multiple mechanisms of action, including direct cancer cell-killing, immunotherapy, and gene therapy. Developing an effective delivery system, such as using carrier cells, is crucial to accelerate the clinical advancement of oncolytic viruses. Mesenchymal stem cells have been heavily investigated as carrier cells due to their inherent tumor tropism.
Article
Genetics & Heredity
Beatrice Tolksdorf, Sina Zarif, Juergen Eberle, Ahmet Hazini, Babette Dieringer, Franziska Jonsson, Florian Kreppel, Jens Kurreck, Henry Fechner
Summary: Silencing of Mcl-1 can overcome TRAIL resistance in melanoma cells and enhance the cytotoxicity of TRAIL-expressing adenovirus. The increase of apoptosis induced by Mcl-1 silencing is the main mechanism for this effect, which occurs in both TRAIL-sensitive and TRAIL-resistant melanoma cells.
JOURNAL OF MOLECULAR MEDICINE-JMM
(2021)
Article
Oncology
Howard L. Kaufman
Summary: Defects in tumor cell IFN gamma signaling are linked to resistance to immune checkpoint inhibitors and increased sensitivity to oncolytic virus infection. Differential expression of innate sensing elements in tumor cells may serve as predictive biomarkers for oncolytic virus immunotherapy in cancer patients.
CLINICAL CANCER RESEARCH
(2021)
Review
Virology
Ifeanyi Kingsley Uche, Konstantin G. Kousoulas, Paul J. F. Rider
Summary: The development of cancer disrupts anti-tumor immunity needed for surveillance and elimination of tumor cells, with immunotherapy aiming to restore or establish these responses. However, a significant proportion of patients do not respond equally to immunotherapies, partially due to the immunosuppressive tumor microenvironment. Current research focuses on mechanisms of immunosuppression in the TME, with the goal of promoting anti-tumor immune responses.
Review
Oncology
Narayanasamy Badrinath, So Young Yoo
Review
Cell & Tissue Engineering
Kshitiz Raj Shrestha, So Young Yoo
STEM CELLS INTERNATIONAL
(2019)
Article
Biochemistry & Molecular Biology
Seon Yeong Chae, Kshitiz Raj Shrestha, Su-Nam Jeong, Geuntae Park, So Young Yoo
Article
Oncology
So Young Yoo, Narayanasamy Badrinath, Hye Lim Lee, Jeong Heo, Dae-Hwan Kang
Article
Chemistry, Multidisciplinary
Young-Il Jeong, So Young Yoo, Jeong Heo, Dae Hwan Kang
Article
Immunology
So Young Yoo, Narayanasamy Badrinath, Su-Nam Jeong, Hyun Young Woo, Jeong Heo
Review
Biochemistry & Molecular Biology
Hyun Young Woo, So Young Yoo, Jeong Heo
Summary: This article provides an overview of the recurrent issues in HCC and the potential of retinoid acid (RA) and its analogues in cancer treatment. It focuses on the clinical characteristics, safety profile and future prospects of the synthetic oral retinoid peretinoin as a secondary chemopreventive agent for HCC.
Review
Immunology
Cao-Sang Truong, So Young Yoo
Summary: Therapeutic cancer vaccines induce long-term immune response by targeting tumor-associated antigens, reducing adverse effects. Vaccinia virus (VV) as an oncolytic virus has promising potential in lung cancer treatment. Non-small cell lung cancer is highly responsive to immunotherapy.
Article
Engineering, Biomedical
Kshitiz Raj Shrestha, Do Hoon Lee, Woojae Chung, Seung-Wuk Lee, Byung Yang Lee, So Young Yoo
Summary: The engineered nanofibrous phage provides therapeutic cues for de novo soft tissue niche engineering, promoting the proper functioning of implanted stem cells and enhancing blood vessel regeneration.
Review
Immunology
Muhammad Joan Ailia, So Young Yoo
Summary: Hepatocellular carcinoma (HCC) is a major cause of cancer-related mortality worldwide. Current therapies have limited effectiveness and undesirable side effects. Oncolytic viruses offer a promising strategy for HCC treatment due to their ability to directly destroy tumor cells and stimulate immune responses. However, there are challenges in viral delivery, tumor dispersion, immune priming, and lack of model systems. Murine cancer models are preferred for studying oncolytic virotherapy. Establishing an accurate in vivo model that mimics the tumor microenvironment is necessary for the development of precise and effective OVT.
Review
Pharmacology & Pharmacy
Palaniyandi Muthukutty, Hyun Young Woo, Murali Ragothaman, So Young Yoo
Summary: Immunotherapy is crucial in fighting cancer and achieving successful remission. Recent advances in cancer immunotherapy delivery techniques have been discussed, along with their future prospects. Meticulously designed delivery methods are necessary to effectively attack cancer cells and expose immune cells to the immune system, while maintaining high therapeutic efficacy and minimizing adverse events.
Review
Biochemistry & Molecular Biology
Muhammad Joan Ailia, Jeong Heo, So Young Yoo
Summary: This systematic review assessed the prognostic significance of PD-1/PDL-1 in HCC. The meta-analysis showed that high PD-1/PDL-1 expression was associated with poor survival outcomes in HCC patients. Additionally, PD-1/PDL-1 expression was found to be associated with certain clinicopathological features. Combination therapy, along with exploring other markers, may improve outcomes in HCC patients receiving PD-1/PDL-1 immunotherapy.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
(2023)
Review
Immunology
Murali Ragothaman, So Young Yoo
Summary: Bacteriophages have emerged as versatile tools in bioengineering, with enormous potential in tissue engineering, vaccine development, and immunotherapy. They can be harnessed for the development of novel DNA vaccines and antigen display systems, providing a highly organized and repetitive presentation of antigens to immune cells. Bacteriophages also have potential in targeting specific molecular determinants of cancer cells.
Article
Virology
Cao-Sang Truong, Palaniyandi Muthukutty, Ho Kyung Jang, Young-Ho Kim, Dong Hoon Lee, So Young Yoo
Summary: Far UV-C light (207-222 nm) can efficiently kill pathogens with potentially no harm to human tissues. A single-wavelength far UV-C (207 nm) lamp has been developed to safely inactivate various respiratory viruses, providing significant potential in reducing COVID-19 infections.
